RU2010138612A - ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR - Google Patents
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR Download PDFInfo
- Publication number
- RU2010138612A RU2010138612A RU2010138612/10A RU2010138612A RU2010138612A RU 2010138612 A RU2010138612 A RU 2010138612A RU 2010138612/10 A RU2010138612/10 A RU 2010138612/10A RU 2010138612 A RU2010138612 A RU 2010138612A RU 2010138612 A RU2010138612 A RU 2010138612A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- acid sequence
- region containing
- variable region
- Prior art date
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 37
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims abstract 22
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims abstract 22
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims abstract 21
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims abstract 21
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002134 immunopathologic effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6653908P | 2008-02-20 | 2008-02-20 | |
| US61/066,539 | 2008-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010138612A true RU2010138612A (ru) | 2012-03-27 |
Family
ID=40984994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010138612/10A RU2010138612A (ru) | 2008-02-20 | 2009-02-19 | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8268972B2 (enExample) |
| EP (2) | EP2826791A3 (enExample) |
| JP (2) | JP2011515073A (enExample) |
| KR (1) | KR20100117120A (enExample) |
| CN (2) | CN101970494B (enExample) |
| AU (1) | AU2009217224B2 (enExample) |
| BR (1) | BRPI0907532A2 (enExample) |
| CA (1) | CA2714296A1 (enExample) |
| ES (1) | ES2562627T3 (enExample) |
| IL (1) | IL207217A (enExample) |
| MX (1) | MX2010009190A (enExample) |
| RU (1) | RU2010138612A (enExample) |
| WO (1) | WO2009103113A1 (enExample) |
| ZA (1) | ZA201005348B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003202297C1 (en) | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| AU2007288118A1 (en) * | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| KR20100117120A (ko) * | 2008-02-20 | 2010-11-02 | 지투 인플레메이션 피티와이 엘티디 | 인간화된 항-Ｃ5ａＲ 항체 |
| AU2009265808B2 (en) | 2008-06-30 | 2014-10-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| WO2011104381A2 (en) * | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| SG183443A1 (en) | 2010-03-01 | 2012-09-27 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| RU2616881C2 (ru) | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US9795121B2 (en) | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
| SI3221359T1 (sl) | 2014-11-17 | 2020-08-31 | Regeneron Pharmaceuticals, Inc. | Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20 |
| BR112017011170A2 (pt) * | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016257929B2 (en) | 2015-05-04 | 2022-10-20 | Cytomx Therapeutics, Inc | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| EP3600421A4 (en) * | 2017-03-23 | 2021-01-06 | The Trustees of The University of Pennsylvania | ANTI-C5A ANTIBODIES AND USES OF THEM |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| KR102387064B1 (ko) * | 2017-12-14 | 2022-04-18 | 코카 크롬 인더스트리 컴퍼니 리미티드 | 냉각롤 및 그것을 사용한 열가소성 수지 시트의 제조 방법 |
| JP2021527062A (ja) * | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| CN109439662B (zh) * | 2018-11-15 | 2020-09-01 | 北京大学第三医院 | 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法 |
| JP7617012B2 (ja) * | 2019-03-14 | 2025-01-17 | モルフォシス・アーゲー | Ｃ５ａＲを標的とする抗体 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0832231A2 (en) | 1995-06-05 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| JP2001511645A (ja) | 1997-01-31 | 2001-08-14 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトＣ５ａ様受容体 |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| AU2002231194A1 (en) | 2000-11-07 | 2002-05-21 | Genetics Institute, Llc | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| WO2002059263A2 (en) | 2000-12-19 | 2002-08-01 | Sunol Molecular Corporation | Transgenic animals comprising a humanized immune system |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| EP1438325B1 (en) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AU2003202297C1 (en) * | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| AU2004304665B2 (en) * | 2003-12-24 | 2009-03-12 | Novo Nordisk A/S | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR |
| WO2005092366A1 (en) * | 2004-03-26 | 2005-10-06 | Promics Pty Limited | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| US7649951B2 (en) | 2006-08-16 | 2010-01-19 | Harris Corporation | System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading |
| JP2010501165A (ja) | 2006-08-22 | 2010-01-21 | ジーツー インフラメイション プロプライエタリー リミテッド | 抗体の作製方法 |
| AU2007288118A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| EP2203180B1 (en) | 2007-10-22 | 2012-11-21 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| KR20100117120A (ko) | 2008-02-20 | 2010-11-02 | 지투 인플레메이션 피티와이 엘티디 | 인간화된 항-Ｃ5ａＲ 항체 |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
-
2009
- 2009-02-19 KR KR1020107020742A patent/KR20100117120A/ko not_active Ceased
- 2009-02-19 EP EP14177321.8A patent/EP2826791A3/en not_active Withdrawn
- 2009-02-19 RU RU2010138612/10A patent/RU2010138612A/ru not_active Application Discontinuation
- 2009-02-19 CN CN200980105691.9A patent/CN101970494B/zh not_active Expired - Fee Related
- 2009-02-19 JP JP2010547002A patent/JP2011515073A/ja active Pending
- 2009-02-19 US US12/866,009 patent/US8268972B2/en not_active Expired - Fee Related
- 2009-02-19 CA CA2714296A patent/CA2714296A1/en not_active Abandoned
- 2009-02-19 AU AU2009217224A patent/AU2009217224B2/en not_active Ceased
- 2009-02-19 ES ES09713373.0T patent/ES2562627T3/es active Active
- 2009-02-19 BR BRPI0907532-1A patent/BRPI0907532A2/pt not_active Application Discontinuation
- 2009-02-19 MX MX2010009190A patent/MX2010009190A/es active IP Right Grant
- 2009-02-19 EP EP09713373.0A patent/EP2254911B1/en not_active Not-in-force
- 2009-02-19 CN CN201410315627.6A patent/CN104193824A/zh not_active Withdrawn
- 2009-02-19 WO PCT/AU2009/000184 patent/WO2009103113A1/en not_active Ceased
-
2010
- 2010-07-26 IL IL207217A patent/IL207217A/en not_active IP Right Cessation
- 2010-07-27 ZA ZA2010/05348A patent/ZA201005348B/en unknown
-
2012
- 2012-08-20 US US13/590,016 patent/US8361468B2/en not_active Expired - Fee Related
- 2012-12-19 US US13/720,685 patent/US8808701B2/en not_active Expired - Fee Related
-
2014
- 2014-04-28 JP JP2014092573A patent/JP6034826B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8268972B2 (en) | 2012-09-18 |
| JP2014193164A (ja) | 2014-10-09 |
| US20120315275A1 (en) | 2012-12-13 |
| EP2826791A3 (en) | 2015-07-29 |
| EP2254911B1 (en) | 2015-11-25 |
| BRPI0907532A2 (pt) | 2015-07-28 |
| AU2009217224B2 (en) | 2014-09-11 |
| ES2562627T3 (es) | 2016-03-07 |
| CN101970494B (zh) | 2015-01-21 |
| US8361468B2 (en) | 2013-01-29 |
| EP2826791A2 (en) | 2015-01-21 |
| EP2254911A4 (en) | 2011-10-19 |
| EP2254911A1 (en) | 2010-12-01 |
| US20130129721A1 (en) | 2013-05-23 |
| IL207217A (en) | 2015-03-31 |
| CN104193824A (zh) | 2014-12-10 |
| MX2010009190A (es) | 2010-09-10 |
| AU2009217224A1 (en) | 2009-08-27 |
| WO2009103113A1 (en) | 2009-08-27 |
| KR20100117120A (ko) | 2010-11-02 |
| JP2011515073A (ja) | 2011-05-19 |
| JP6034826B2 (ja) | 2016-11-30 |
| ZA201005348B (en) | 2011-10-26 |
| US20110190477A1 (en) | 2011-08-04 |
| US8808701B2 (en) | 2014-08-19 |
| CN101970494A (zh) | 2011-02-09 |
| CA2714296A1 (en) | 2009-08-27 |
| IL207217A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010138612A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR | |
| JP2011515073A5 (enExample) | ||
| MX2024002158A (es) | Anticuerpos anti-ccr8 y usos de estos. | |
| FI3551660T3 (fi) | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
| JP2016520619A5 (enExample) | ||
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| ME02629B (me) | Anti-cs antitijela sa poboljšanom farmakokinetikom | |
| NZ603883A (en) | Method for preparing antibodies having improved properties | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| HRP20241660T1 (hr) | Formulacija protutijela anti-cgrp | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| NZ597676A (en) | Crystalline anti-hTNFalpha antibodies | |
| EA023665B1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
| NZ574978A (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| JP2015526440A5 (enExample) | ||
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| CA2189015A1 (en) | Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases | |
| PH12022550211A1 (en) | Anti-pd-1 antibody and medical use thereof | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| IL269387A (en) | Pan-elr cxc chemokine antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150507 |